asdzxc

[asdzxc @jasdzxc01]

@AnthonyDon_ Lesssgoooooooo

[Mr_Shares_Expert @MrShare_expert]

#1AD #CART #agggressiveCancer

Excited to be on this journey

2 * COMPLETE RESPONSE (continued 22months and 6 months after treatment), something totally unheard of... nuff said😏

[Pigeon @CheatChart]

$DVL - 4.1/4.2 cents, DYOR
*Working on a breakout

[asdzxc @jasdzxc01]

@asxpeasant Thanks for the feedback!! It looks exciting

[YellowStripes💥 @YellowStripeASX]

$DVL (47M MC) is the Only #ReRam #RRAM Play in #ASX behind $WBT ($1.7B MC)

💥 S$120 Million spent on $DVL #RRAM Tech since 2019, Partnerships with #ITRI @NTUsg @TechnionLive

💥Ex $AYA CEO Matt Regan is now running $DVL

[asdzxc @jasdzxc01]

@andreysuperior 847 views does not generate $3,000. YouTube kids content has some of the lowest RPM due to COPPA ad restrictions. Your headline says $37k/month, your story says $120k/month. These numbers are made up.

[TheGladiator @TheGladiatorHC]

$DVL's plan of giving robotics a digital nervous system rests on one thing, a manufacturable RRAM chip, and that's exactly what just happened.Three material stacks qualified and confirmed they can be built on standard CMOS lines, with a Tier-1 foundry tape-out locked for Q3 2026.

[asdzxc @jasdzxc01]

$DVL the sleeping giant. Next best RRAM play after $WBT . De risked and on its way to 22nm with a Tier1 foundry.

[Pitt Street Research @PSR_Insights]

We just published a research update on @dorsavi (ASX: $DVL): DVL hits the road toward 22nm ReRAM as it has just cleared what is probably the single largest de-risking event hanging over its ReRAM program to date!

We reiterate our 22 cent/share valuation.
https://t.co/H6z6ayzwEP

[asdzxc @jasdzxc01]

@TheGladiatorHC There is background song

[asdzxc @jasdzxc01]

@QPMEnergy @StockheadAU Disaster for shareholders

[AdAlta Limited @AdAlta1AD]

BZSD1901 CAR-T: new hope for mesothelioma patients - webinar replay

BZDS1901 has already delivered impressive responses in clinical trials, including difficult to achieve complete tumour clearance. This webinar explores how this could transform mesothelioma outcomes

[asdzxc @jasdzxc01]

Register to hear all about AdAlta incredible CAR-T Cancer treatment. Excellent results from early clinical trials #1AD

[AdAlta Limited @AdAlta1AD]

AdAlta (ASX:1AD) Investor Webinar: New hope for mesothelioma patients - BZDS1901 clinical update

Monday, 11 May 2026

2:30 – 3:15 pm AEST

Register (free) here: https://t.co/mFzi4LUeZA

[Mr_Shares_Expert @MrShare_expert]

#1AD #Cancer #mesothelioma #CarT #AggressiveCancer #BIO #webinar

took part in the placement at $0.004 plus topped up more today on Market..

Exciting little Bio Company currently working on potential treatment of mesothelioma, an Aggressive form of Lung Cancer using their cutting edge CAR-T technology (BZDS1901)

💠Response rates are almost double those seen with current treatments
💠packs the potential to significantly improve response rates and even achieve rare complete tumour clearances in advanced mesothelioma patients
💠14 mesothelioma patients treated
💠one patient with complete response
💠Five of the ten patients receiving the highest doses of BZDS1901 are seeing tumour shrinkage of more than 30% (50% Overall Response Rate)
💠Tumours 5cm in size before BZDS1901 are now undetectable in two out of ten of these patients (20%, achieving criteria for a Complete Response) – highly unusual in patients who have already failed prior therapy

Heading into Australian Phase 1 clinical trials.. 👏

Register today
Investor Webinar: New hope for mesothelioma patients - BZDS1901 clinical update
https://t.co/ZL6IXSpKBO

[Mr_Shares_Expert @MrShare_expert]

#1AD

Not a molecule left of the cancer in this patient.. complete response, not something you ever get in aggressive forms of cancer...

No wonder am excited about this little #bio company & accumulating..

CR done at $0.004....

Lets get that clinical trial going..

[Mr_Shares_Expert @MrShare_expert]

#1AD #cart #Cancer #BIO

I have been loading in this #bio , I believe it has the potential to generate baggs..

Complete fucking response in a patient in one of the most aggressive cancers around...

Heading into Australian pahse 1 clinical trials... 👏👏

Imo dyor..

[RM💰 @RawMinerals]

#1AD #1ADO capital raise ✅️, Cashed Up to scale up BZDS1901, a highly differentiated CAR-T therapy for mesothelioma and other solid cancers,

Placement to supports advancement of BZDS1901 towards key US FDA
regulatory and Australian manufacturing milestones✅️

Early clinical results reported in advanced, treatment-resistant mesothelioma, including multiple tumour responses and two patients achieving complete tumour clearance (Complete Response)✅️

One Complete Response patient remains alive 22 months after treatment, with no reported tumour recurrence.✅️

AdAlta, Oribiotech and Cell Therapies signed an MoU to bring Oribiotech’s IRO automated cell therapy manufacturing platform to Australia and Asia Pacific.✅️

AdAlta and Cell Therapies signed the first Work Order to transfer BZDS1901 manufacturing to Australia, supporting future Australian Phase 1 clinical trials✅️

UltraLowMc | $12m MC | DYOR | #Cancer #Biotechnology #Mesothelioma #CAR-T

[ASX Insights @ASXnCrypto]

#1AD #ASX CAR-T NEWS
$10M MC💥

[CJTJ @cjtj575]

#1AD #ASX #Cancer #Celltherapy

#Watchthisspace!!! cheers again @YellowStripeASX

[CJTJ @cjtj575]

Great posting as usual mate @YellowStripeASX 🙏
great news for the company today
#1AD #ASX the sleeping GIANT!! IMO